Michael P. Rettig, Ph.D.

2000 Purdue University, West Lafayette, IN, United States 
ligand-targeted imaging and therapeutic agents for the diagnosis and treatment of important human diseases
"Michael Rettig"
Mean distance: 12.9


Sign in to add mentor
Philip S. Low grad student 2000 Purdue
 (Examination of the erythrocyte membrane during senescence and coagulation.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ghobadi A, Foley NC, Cohen J, et al. (2023) Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Advances
Xiang J, Devenport JM, Carter AJ, et al. (2023) An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. Leukemia
Crees ZD, Rettig MP, Bashey A, et al. (2023) Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Advances
Crees ZD, Rettig MP, DiPersio JF. (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Therapeutic Advances in Hematology. 14: 20406207231174304
Ferraro F, Miller CA, Christensen KA, et al. (2021) Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proceedings of the National Academy of Sciences of the United States of America. 118
Persaud SP, Ritchey JK, Kim S, et al. (2021) Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. The Journal of Clinical Investigation
Xiang J, Shi M, Fiala MA, et al. (2021) Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Advances
Cancilla D, Rettig MP, DiPersio JF. (2020) Targeting CXCR4 in AML and ALL. Frontiers in Oncology. 10: 1672
Uy GL, Aldoss I, Foster MC, et al. (2020) Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. Blood
Oza A, Rettig MP, Powell P, et al. (2020) Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. Blood Advances. 4: 2387-2391
See more...